An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART)

Approximately one in ten couples of reproductive age experiences infertility. Infertility may be caused by problems in men, in women or in both. A number of techniques can be used depending on the duration and type of infertility problems. The treatment of ovulation induction (OI) uses the help of exogenous gonadotrophins such as follicle stimulating hormone (FSH), luteinizing hormone (LH) and hCG in order to stimulate follicles and release oocytes for fertilization in the fallopian tubes.

Assisted reproductive technologies (ARTs), including in-vitro fertilization (IVF) and intra- cytoplasmic sperm injection (ICSI), increases the chances of success to obtain more than one embryo. In order to obtain more than one embryo, it is necessary to stimulate the growth and maturation of several follicles. Such a multiple follicular development is obtained by daily administration of a follicle stimulating hormone (r-hFSH, Gonal-F). When these follicles have reached a large enough size, the role of hCG is to achieve final oocyte maturation and initiation of follicular luteinization.

Serono International S.A. has developed a pharmaceutical preparation of human chorionic gonadotrophin (hCG) for clinical use through the application of recombinant DNA technology. The resulting product is choriogonadotrophin alpha, a pure recombinant human chorionic gonadotrophin (r-hCG). The corresponding drug product is marketed under the tradename Ovidrel. Ovidrel (choriogonadotrophin alpha for injection) has been approved in the United States, in the European Union and Australia.

OBJECTIVES The objective of this study was to collect safety information in order to confirm the already known profile of r- hCG (Ovidrel).

Inclusion criteria

• Infertile women desiring a pregnancy
• Subjects whose baseline hormonal values were within normal ranges as per local practice
• Subjects who were willing and able to comply with the protocol for the duration of the study
• Subjects who had given written informed consent, prior to treatment, with the understanding that consent might be withdrawn at any time without prejudice

Exclusion criteria

• Subjects with clinically significant disease
• Subjects who were known to be infected by human immunodeficiency virus (HIV), Hepatitis B or C
• Subjects who had any medical condition, which in the judgment of the investigator, may interfere with the absorption, distribution, metabolism or excretion of study drug
• Subjects with severe endometriosis
• Subjects with abnormal, undiagnosed gynaecological bleeding
• Subjects who had any contra-indication to being pregnant or carrying a pregnancy to term
• Subjects who were pregnant or breast-feeding at the beginning of the cycle. Confirmation that the subject was not pregnant was to be established by a negative urine or serum pregnancy test in the 7 days prior to Study Day1
• Subjects with prior hypersensitivity to hCG preparations or one of their excipients
• Subjects with uncontrolled thyroid or adrenal dysfunction
• Subjects with uncontrolled organic intracranial lesion such as a pituitary tumour
• Subjects with ovarian cyst or enlargement of undetermined origin
• Subjects with sex hormone dependent tumors of the reproductive organs and breasts